Toward an integrated neurobiology of panic disorder

Journal of Clinical Psychiatry

Volumn 58, Issue SUPPL. 2, 1997, Pages 4-11

  Goddard, Andrew W ^a,b   Charney, Dennis S ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Yale University School of Medicine   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; CARBON DIOXIDE; CHOLECYSTOKININ; CLONAZEPAM; IPSAPIRONE; LACTIC ACID; NEUROPEPTIDE Y; NORADRENALIN; SEROTONIN;

ANXIETY NEUROSIS; BEHAVIOR THERAPY; COGNITION; FUNCTIONAL ANATOMY; HUMAN; NEUROANATOMY; NEUROBIOLOGY; NEUROPHYSIOLOGY; PANIC; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

AMYGDALA; ANXIETY; BRAIN; DIAGNOSTIC IMAGING; FEAR; HUMANS; LOCUS COERULEUS; MODELS, NEUROLOGICAL; NEURAL NETWORKS (COMPUTER); NEUROBIOLOGY; NEUROPEPTIDES; NOREPINEPHRINE; PANIC DISORDER;

EID: 0030938925     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Keller MB, Hanks DL. Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:551-570
2. Gorman JM, Liebowitz MR, Fyer AJ, et al. A neuroanatomical hypothesis of panic disorder. Am J Psychiatry 1989;146:148-162
3. Pratt JA. The neuroanatomical basis of anxiety. Pharmacol Ther 1992; 55:149-181
4. Charney DS, Deutsch A. A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 1996;10, 3/4:419-446
5. Davis MD. The role of the amygdala in conditioned fear. In: Aggleton JP, ed. The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction. New York, NY: Wiley-Liss; 1992:255-306
6. Kaada BR. Stimulation and regional ablation of the amygdaloid complex with reference to functional representations. In: Eleftheriou BE, ed. The Neurobiology of the Amygdala. New York, NY: Plenum Press; 1972: 205-281
7. Dunn JD, Whitener J. Plasma corticosterone responses to electrical stimulation of the amygdaloid complex: cytoarchitectural specificity. Neuroendocrinology 1986;42:211-217
8. Gloor P. Role of the amygdala in temporal lobe epilepsy. In: Aggleton JP, ed. The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction. New York, NY: Wiley-Liss; 1992:505-538
9. Le Doux JE. Emotion and the amygdala. In: Aggleton JP, ed. The Amygdala: Neurobiological Aspects of Emotion, Memory and Mental Dysfunction. New York, NY: Wiley-Liss; 1992:339-352
10. Holets VR. Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex, and hypothalamus. Neuroscience 1988;24:893-906
11. Valentino RJ, Aston-Jones GS. Physiologic and anatomical determinants of locus coeruleus discharge: behavioral and clinical implications. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:373-387
12. Aston-Jones G, Shipley MT, Pieribone VA, et al. The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 1986;234:734-737
13. Rasmussen K, Aghajanian GK. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Res 1989;505:346-350
14. Fillenz M. Noradrenergic Neurons. Cambridge, United Kingdom: Cambridge University Press; 1990
15. Redmond DE Jr, Huang YH, Snyder DR, et al. Behavioral effects of stimulation of the locus coeruleus in the stumptail monkey (Macaca arctoides). Brain Res 1976;116:502-510
16. Abercrombie ED, Jacobs BL. Single-unit response of noradrenergic neurons in the locus coeruleus of freely moving cats, I: acutely presented stressful and nonstressful stimuli. J Neurosci 1987;7:2837-2843
17. Abercrombie ED, Zigmond MJ. Modification of central catecholaminergic systems by stress and injury: functional significance and clinical implications. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:355-363
18. Svensson TH. Peripheral autonomic regulation of locus coeruleus neurons in the brain: putative implications for psychiatry and psychopharmacology. Psychopharmacology (Berl) 1987;92:1-7
19. Phillips RG, Le Doux JP. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 1992; 106:274-285
20. Bandler R, Shipley MT. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression. Trends Neurosci 1994; 17:379-389
21. Jenke F, Moreau JL, Martin JR. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 1995;57:181-191
22. Thorpe SJ, Rolls ET, Maddison S. The orbitofrontal cortex: neuronal activity in the behaving monkey. Exp Brain Res 1983;49:93-115
23. Baleydier C, Mauguiere F. The duality of the cingulate gyrus in the monkey: neuroanatomical study and functional hypothesis. Brain 1980;103: 525-554
24. Benkelfat C, Bradwejn J, Meyer E, et al. Functional neuroanatomy of CCK-4-induced anxiety in normal healthy volunteers. Am J Psychiatry 1995;152:1180-1184
25. Rauch SL, Savage CR, Alpert NM, et al. A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry 1995; 52:20-28
26. Maricle RA, Sennhauser S, Burry M. Panic disorder associated with right parahippocampal infarction. J Nerv Ment Dis 1991;6:374-375
27. Dietch JT. Cerebral tumor presenting with panic attacks. Psychosomatics 1984;25:861-863
28. Lepola U, Nousiainen U, Puranen M, et al. EEG and CT findings in patients with panic disorder. Biol Psychiatry 1990;28:721-727
29. Ontiveros A, Fontaine R, Breton G, et al. Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. J Neuropsychiatry Clin Neurosci 1989;1:404-408
30. Reiman EM, Raichle ME, Butler FK, et al. A focal brain abnormality in panic disorder, a severe form of anxiety. Nature 1984;310:683-685
31. Nordahl TE, Semple WE, Gross M, et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 1990; 3:261-272
32. Woods SW, Koster K, Krystal JK, et al. Yohimbine alters regional cerebral blood flow in panic disorder [letter]. Lancet 1988;2:678
33. De Cristofaro MR, Sessarego A, Pupi A, et al. Brain perfusion abnormalities in drug naive, lactate-sensitive panic patients. Biol Psychiatry 1993; 33:505-512
34. Kaschka W, Feistel H, Ebert D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 1995; 29:427-434
35. Dager SR, Strauss WL, Marro KI, et al. Proton magnetic resonance spectroscopy investigation of hyperventilation in subjects with panic disorder and comparison subjects. Am J Psychiatry 1995;152:666-672
36. Charney DS, Bremner JD, Redmond DE. Noradrenergic neural substrates for anxiety and fear: clinical associations based on preclinical research. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:387-397
37. Charney DS, Woods SW, Krystal JH, et al. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 1992;86:273-282
38. Uhde TW, Vittone BJ, Siever LJ, et al. Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 1986;21:1077-1081
39. Pohl R, Yeragani VK, Balon R, et al. Isoproterenol-induced panic attacks. Biol Psychiatry 1988;24:891-902
40. Handley SL. 5-hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 1995;66:103-148
41. Goddard AW, Woods SW, Charney DS. A critical review on the role of noradrenaline in panic disorder: focus on its interaction with serotonin. In: Westenberg HGM, Murphy DL, Den Boer JA, eds. Advances in the Neurobiology of Anxiety Disorders. West Sussex, England: John Wiley & Sons. In press
42. Price LH, Goddard AW, Barr L, et al. Pharmacologic challenges in anxiety disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995: 1311-1325
43. Goddard AW, Woods SW, Sholomskas DE, et al. Effects of the serotonin reuptake inhibitor fluvoxamine on noradrenergic function in panic disorder. Psychiatry Res 1993;48:119-133
44. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry 1993;50:306-317
45. Gorman JM, Fyer MR, Liebowitz MR, et al. Pharmacologic provocation of panic attacks. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:985-993
46. Paul SM. GABA and glycine. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:87-94
47. Roy-Byrne PP, Cowley DS, Greenblatt DJ, et al. Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:534-538
48. Nutt DJ, Glue P, Lawson CW, et al. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 1990;47:917-925
49. Shekhar A, Keim S, Simon JR, et al. GABA dysfunction in the dorsomedial hypothalamus provokes physiological response to lactate infusion. Pharmacol Biochem Behav. In press
50. Roy-Byrne PP, Cowley DS, Hommer D, et al. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. Psychopharmacology 1992;109:153-156
51. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 1991;48: 603-610
52. Abelson JL, Nesse RM. Pentagastrin infusions in patients with panic disorder, I: symptoms and cardiovascular responses. Biol Psychiatry 1994;36: 73-83
53. Bradwejn J, Koszycki D, Couetoux du Tertre A, et al. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 1994;51:486-493
54. B antagonist, in panic disorder. Biol Psychiatry 1995;37: 462-466
55. Jolkkonen J, Lepola U, Bissette G, et al. CSF corticotropin-releasing factor is not affected in panic disorder. Biol Psychiatry 1993;33:136-138
56. Boulenger J, Jerabek I, Jolicoeur FB, et al. Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 1996;153: 114-116
57. Wahlestedt C, Heilig M. Neuropeptide Y and related peptides. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:543-553